EX-99.1 2 exhibit_99-1.htm EARNINGS RELEASE exhibit_99-1.htm
Exhibit 99.1

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

Pivotal Phase III Trial Primary Endpoints Achieved for SCOLR’s 12-Hour Ibuprofen
 
BOTHELL, WA, November 7, 2008, - SCOLR Pharma, Inc. (AMEX: DDD) today reported financial results for the three and nine months ended September 30, 2008.  The Company will host a live conference call today, November 7, 2008, at 11:30 a.m. (Eastern Standard Time).

Daniel O. Wilds, SCOLR Pharma's President and CEO, said, “We had a very productive third quarter making significant progress advancing our lead product candidates and securing additional non-dilutive operating capital while maintaining financial discipline.  Most importantly, yesterday we reported favorable top-line results from our pivotal Phase III trial to evaluate the safety and efficacy of our 12 hour CDT® 600 mg extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The trial incorporated FDA special protocol assessment design elements, met both co-primary endpoints (p<0.0001), and had no significant adverse events.  This successful trial is an extremely important milestone for the Company. We expect that the successful results of this study will focus the attention of potential partners and facilitate an alliance for our lead product candidate.”

Also during the quarter, SCOLR submitted an Abbreviated New Drug Application (ANDA) for a 120 milligram 12-hour pseudoephedrine tablet based on our patented Controlled Delivery Technology (CDT®) platform. Subsequently, we reported that the U.S. FDA had accepted our submission for review. This is the first product approval application filed by SCOLR Pharma, and, if approved, would further demonstrate the novel advantages of our proprietary drug delivery technology.

The Company also completed its previously announced lease termination and buyout transaction under which we received $4.1 million and successfully relocated its corporate headquarters to a more cost effective and better equipped facility.”

Mr. Wilds concluded, “We are very encouraged by our achievement of important business and clinical milestones during the past quarter. By continuing to focus on partnering our lead product candidates, limiting additional drug development initiatives to those already partnered and in active collaborations, we expect that the net proceeds from the lease buyout and our current financial resources together with continuing expense management should be sufficient to fund our operations through 2009.”

Total revenues, which consist of royalty revenue from our collaboration agreements, increased 14%, or $28,834 to $236,308 for the three months ended September 30, 2008, compared to $207,474 for the same period in 2007. This increase is primarily due to higher royalty income from our relationship with Perrigo.

Total revenues decreased 55% or $968,013 to $781,435 for the nine months ended September 30, 2008, compared to $1.7 million for the same period in 2007. The higher total revenues for 2007 were primarily due to approximately $621,222 of research and development fees and licensing revenues from an agreement terminated in the first quarter of 2007.

Net income for the three months ended September 30, 2008, was $890,370 compared to a net loss of ($3.1) million for the same period in 2007.  Net loss for the nine months ended September 30, 2008, decreased 55%, or $3.9 million to $3.2 million, compared with a net loss of $7.1 million for the same period in 2007. The decrease in the net loss was primarily due to the $4.0 million net gain from the termination of the lease on our corporate facility.

In May 2008, we entered into an agreement to terminate the lease of our corporate facility for $4.1 million. Under the terms of the agreement, $1.0 million was paid upon execution of the agreement and the remaining $3.1 million was paid in September when we vacated our premises. We recognized in operating expense, the gain of $4.1 million and $116,867 of expense related to the new lease and our relocation to the new facility in September 2008.

 
1
 
 

Total operating expenses for the third quarter of 2008 were $(611,506), which included $4.0 million net lease termination gain, compared to $3.5 million in the same period in 2007. Total operating expenses decreased 55% to $4.2 million for the nine months ended September 30, 2008, from $9.4 million for the same period in 2007. The decreases in operating expenses were primarily due to the net gain of $4.0 million from the lease termination and surrender agreement associated with our corporate facility.
 
SCOLR had approximately $8.9 million in cash and cash equivalents, and $564,000 in restricted cash as of September 30, 2008. The Company is investing its cash and cash equivalents in government-backed securities.

Conference Call

As previously announced, SCOLR Pharma will host a conference call on November 7, 2008, at 11:30 a.m. (Eastern Standard Time). Shareholders and other interested parties may participate in the conference call by dialing +1-888-713-4215 (domestic) or +1 617-213-4867 (international) and entering access code 67625263, a few minutes before 11:30 a.m. EST on November 7, 2008. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through November 21, 2008, by dialing +1-888-286-8010 (domestic) or +1 617-801-6888 (international) and entering access code 60696221. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma’s corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning our ability to fund our operations through 2009, the success of our products in the marketplace and in clinical trials and the availability of potential partners. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including unanticipated costs and expenses associated with our product development and clinical activities, reductions in our royalty revenues, our ability to successfully develop new formulations and complete research and development, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.

 
2
 
 

Financial Information
 
SCOLR Pharma, Inc.
 
BALANCE SHEET
 
   
September 30,
2008
(Unaudited)
    
December 31,
2007
  
ASSETS
            
Current Assets
            
Cash and cash equivalents
  
$
8,908,986
    
$
11,825,371
  
Accounts receivable
    
244,214
      
225,900
  
Interest and other receivables
    
—
      
16
  
Prepaid expenses and other assets
    
323,407
      
432,213
  
Total current assets
    
9,476,607
      
12,474,500
  
                 
Property and Equipment — net of accumulated depreciation of $1,213,775 and $964,738, respectively
    
502,510
      
748,931
  
Intangible assets — net of accumulated amortization of $443,435 and $385,452, respectively
    
522,403
      
464,023
  
Restricted cash
    
564,000
      
—
  
   
$
11,065,520
    
$
13,687,454
  
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current Liabilities
                
Accounts payable
  
$
324,890
    
$
757,420
  
Accrued expenses
    
738,330
      
586,849
  
Current portion of term loan
    
85,831
      
80,047
  
Total current liabilities
    
1,149,051
      
1,424,316
  
Long-term portion of term loan
    
46,004
      
111,119
  
Total liabilities
    
1,195,055
      
1,535,435
  
                 
Commitments and Contingencies
                
                 
Stockholders’ Equity
                
Preferred stock, authorized 5,000,000 shares, $.01 par value, none issued or outstanding
    
—
      
—
  
Common stock, authorized 100,000,000 shares, $.001 par value, 41,130,270 and 40,991,385 issued and outstanding as of September 30, 2008, and December 31, 2007, respectively
    
41,130
      
40,991
  
Additional paid-in capital
    
70,879,940
      
69,945,666
  
Accumulated deficit
    
(61,050,605
)
    
(57,834,638
)
Total stockholders’ equity
    
9,870,465
      
12,152,019
  
   
$
11,065,520
    
$
13,687,454
  
 
 
3
 
 

SCOLR Pharma, Inc.
 
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
 
   
Three months ended
September 30,
    
Nine months ended
September 30,
  
   
2008
    
2007
    
2008
    
2007
  
Revenues
                        
Licensing fees
  
$
—
    
$
—
    
$
—
    
$
173,077
  
Royalty income
    
236,308
      
207,474
      
781,435
      
955,149
  
Research and development income
    
—
      
—
      
—
      
621,222
  
Total revenues
    
236,308
      
207,474
      
781,435
      
1,749,448
  
                                 
Operating expenses
                                
Marketing and selling
    
116,840
      
198,520
      
545,579
      
673,776
  
Research and development
    
2,307,103
      
2,236,852
      
4,387,636
      
5,410,226
  
General and administrative
    
  947,684
      
1,017,177
      
3,242,614
      
3,305,918
  
     
3,371,627
      
3,452,549
      
8,175,829
      
9,389,920
  
Facility lease termination
                                
Gain from lease buyout
    
(4,100,000
)
    
—
      
(4,100,000
)
    
—
  
Expenses related to relocation and lease Buyout
    
116,867
      
—
      
116,867
      
—
  
Total facility lease buyout                                                  
    
(3,983,133
)
    
—
      
(3,983,133
)
    
—
  
Total operating expenses
    
  (611,506
)
    
3,452,549
      
4,192,696
      
9,389,920
  
Income or (loss) from operations
    
   847,814
      
(3,245,075
)
    
(3,411,261
)
    
(7,640,472
)
                                 
Other income (expense)
                                
Interest income
    
45,858
      
160,080
      
205,530
      
550,402
  
Interest expense
    
(3,393
)
    
(5,191
)
    
(11,565
)
    
(10,967
)
Other
    
   91
      
—
      
1,329
      
2,941
  
Total other income (expense)                                                    
    
42,556
      
154,889
      
195,294
      
542,376
  
Net income or (loss)
  
$
   890,370
    
$
(3,090,186
)
  
$
(3,215,967
)
  
$
(7,098,096
)
Net income (loss) per share, basic and diluted
  
$
 .02
    
$
(0.08
)
  
$
(0.08
)
  
$
(0.19
)
Shares used in computing basic net income (loss) per share
    
41,043,770
      
38,153,316
      
41,037,128
      
38,123,071
  
Shares used in computing diluted net income (loss) per share
    
41,561,623
      
38,153,316
      
41,037,128
      
38,123,071
  
 
Contact:
Investor Relations:
Cameron Associates
Kevin McGrath
212.245.4577
Kevin@cameronassoc.com
 
 4